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Antimicrobial Susceptibility of Bacillus anthracis Isolates Associated with 
Intentional Distribution in Florida, New Jersey, New York, Pennsylvania, 
Virginia, and Washington, D.C., September - October, 2001
The antimicrobial susceptibility patterns of eleven Bacillus anthracis isolates associated with intentional exposures 
on the east coast have been determined. The susceptibility patterns of all the isolates were similar and are 
described below. CDC will be issuing updated treatment recommendations for anthrax and will disseminate them 
as soon as they are completed.
Ciprofloxacin <0.06 g/ml (susceptible)
Tetracycline = 0.06 g/ml (susceptible)
Doxycycline = 0.03 g/ml (susceptible)
Penicillin <0.06 g/ml - 0.12ug/ml (susceptible but see below)
Amoxicillin < 0.03 g/ml (susceptible but see below)
Erythromycin = 1 g/ml (intermediate)
Azithromycin =2 g/ml (borderline susceptible)
Clarithromycin =0.25 g/ml (susceptible)
Rifampin = 0.5 g/ml (susceptible)
Clindamycin <0.5 g/ml (susceptible)
Vancomycin = 1-2 g/ml (susceptible)
Chloramphenicol = 4 g/ml (susceptible)
Ceftriaxone = 16 -32 g/ml (intermediate or resistant)
The penicillin MICs were <0.06 to 0.12 g/ml, which, using the NCCLS staphylococcal breakpoint for penicillin, 
would be considered susceptible (resistance is defined as >0.25 g/ml).
All of the B. anthracis isolates were also susceptible to ciprofloxacin (MIC< 0.06 g/ml), chloramphenicol (MIC = 4 
g/ml), tetracycline (MIC=0.06 g/ml), doxycycline (MIC=0.06 g/ml), rifampin (MIC<0.5 g/ml), and vancomycin (MIC 
1-2 g/ml).
Although there are no amoxicillin breakpoints defined for staphylococci by NCCLS, the amoxicillin results (MIC 
<0.03 g/ml) were considered susceptible for B. anthracis. However, the erythromycin MICs of all eleven strains of 
B. anthracis would be categorized as intermediate (MIC= 1 g/ml ). The MICs to clarithromycin (MIC=0.25 g/ml) 
and azithromycin (MIC=2 g/ml) are susceptible (but azithromycin MICs are at the susceptible breakpoint). Using 
the NCCLS ceftriaxone breakpoints designated for gram-negative organisms (since there are no breakpoints 
specifically for ceftriaxone for staphylococci) all isolates would be considered as intermediate (MIC =16 ug/ml) or 
resistant (MIC=32 g/ml). These MICs suggest the presence of a cephalosporinase in the isolates. Additional 
studies are in progress to define the beta-lactamases of B. anthracis.
Conclusions
The current B. anthracis strains associated with the intentional exposures are susceptible to ciprofloxacin and 
doxycycline, the two drugs approved for post-exposure prophylaxis to B. anthracis and recommended as part of 
initial therapy of inhalational or cutaneous anthrax.
The current strains also are susceptible to chloramphenicol, clindamycin, rifampin, vancomycin, and 
clarithromycin, but limited or no data exists regarding the use of these agents in the treatment or prophylaxis of B. 
anthracis infections.
Cephalosporins should not be used for post-exposure prophylaxis or treatment of B. anthracisinfections.
The likelihood of a beta-lactamase induction event that would increase penicillin MICs is significantly higher in 
infections where high concentrations of organisms are present. Thus, treatment of known B. anthracis infections 
with a penicillin type drug alone (i.e., penicillin G, ampicillin, etc.) in the setting where high concentrations of 
organisms are present is a concern.
The likelihood of a beta-lactamase induction event that would increase penicillin MICs is lower when only small 
numbers of vegetative cells are present, such as during post exposure prophylaxis. Thus, amoxicillin or penicillin 
VK  may be an option for post-exposure prophylaxis where ciprofloxacin or doxycycline are contraindicated.
Additional studies are in progress to assess the susceptibility of the penicillinase activity observed in these strains 
to beta-lactamase inhibitors.
Clinical experience is limited, but combination therapy with two or more antimicrobials may be appropriate in 
patients with severe infection.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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